BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients
Status:
Withdrawn
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial will determine the recommended dose and activity of BNC105P for
patients with partially platinum sensitive ovarian cancer in first or second relapse.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Hoosier Cancer Research Network
Collaborators:
Australia New Zealand Gynaecological Oncology Group Bionomics Limited University of Sydney